WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006081740) THE SYNERGISTICALLY PHARMACEUTICAL COMPOSITION OF BAICALEIN AND BAICALIN FOR INHIBITING TUMOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/081740    International Application No.:    PCT/CN2006/000088
Publication Date: 10.08.2006 International Filing Date: 20.01.2006
IPC:
A61K 31/352 (2006.01), A61K 31/7048 (2006.01), A61P 35/02 (2006.01), A61P 35/04 (2006.01)
Applicants: SHANGHAI GLORIAYX BIOPHARMACEUTICALS CO., LTD [CN/CN]; No. 351 Guo-shou-jing Road, Zhangjiang Hi-Tech Park, Shanghai 201203 (CN) (For All Designated States Except US).
WU, Yixin [CN/CN]; (CN) (For US Only)
Inventors: WU, Yixin; (CN)
Agent: SHANGHAI XIN TIAN PATENT AGENT CO., LTD.; Rm 1606, N0. 59, Nan Chang Road Shanghai 200020 (CN)
Priority Data:
200510023724.9 01.02.2005 CN
200510025554.8 29.04.2005 CN
Title (EN) THE SYNERGISTICALLY PHARMACEUTICAL COMPOSITION OF BAICALEIN AND BAICALIN FOR INHIBITING TUMOR
(FR) PRÉPARATION PHARMACEUTIQUE SYNERGIQUE CONTENANT DE LA BAICALÉINE ET DE LA BAICALINE ET DESTINÉE À L'INHIBITION D'UNE TUMEUR
(ZH) 抗肿瘤的黄苓甙元和黄苓甙协同药物组合物
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition having synergistical anti-cancer effect which comprising baicalein and the compound of general formula (I) as followed , wherein the molar ratio of baicalein and the compound of the general formula (I) is in the range from 1:1 to 1:4: Wherein, R1 is glucuronic radical , R2 is hydrogen or hydroxy. The present invention also relates to the method for manufacturing the pharmaceutical composition and the use thereof.
(FR)La présente invention concerne une préparation pharmaceutique présentant un effet anticancéreux synergique et comprenant de la baicaléine ainsi que le composé de formule générale (I) ci-après, le rapport molaire de la baicaléine sur le composé de formule générale (I) étant compris entre 1:1 et 1:4 où R1 représente un radical glucuronique, R2 représente un atome d'hydrogène ou un groupement hydroxy. La présente invention concerne également une méthode de fabrication de ladite préparation pharmaceutique ainsi que l'emploi de ladite préparation.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)